Millipore Sigma Vibrant Logo

119137 Adenosine A2A Receptor Agonist I, CGS 21680, Hydrochloride - CAS 124182-57-6 - Calbiochem

119137
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
119137-5MG
Récupération des données relatives à la disponibilité...
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      Flacon en verre 5 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      Demander le prix
      Description
      OverviewA xanthin derivative that acts as a potent agonist of adenosine A2A receptors (Ki = 27 nM). Exhibits reduced affinity for A2B receptors (Ki = 67 nM), but offers greater selectivity over A1R (Ki = 290 nM) and A3R (88.8 µM). Exerts an anti-inflammatory effect during chronic inflammation and ameliorates the tissue damage associated with collagen-induced arthritis. Also shown to reduce CCR7 Protein Expression in THP1 macrophages. Shown to delay the progressive deterioration of motor performance and prevent a reduction in brain weight in murine model of Huntington's disease. Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
      Catalogue Number119137
      Brand Family Calbiochem®
      SynonymsCGS-21680, CGS21680, 3-(4-(2-((6-amino-9-((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl)amino)ethyl)phenyl)propanoic acid
      References
      ReferencesWillians, A. J., et al. 2012. Inflammation. 35, 614.
      Mazzon, E. et al. 2011. J Rheumatol. 38, 2119,
      Martire, A., et al. 2007. Neurosci Lett. 417, 78.
      Chou, S. Y., et al, 2005. Journ Neurochem. 93, 310.
      Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol.362 382.
      Phillis, J. W., et al. 1990.Brain Res. 509, 328.
      Product Information
      CAS number124182-57-6
      FormWhite solid
      FormulationSupplied as a hydrochloride salt.
      Hill FormulaC₂₃H₂₉N₇O₆ • HCl
      Chemical formulaC₂₃H₂₉N₇O₆ • HCl
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥96% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Adenosine A2A Receptor Agonist I, CGS 21680, Hydrochloride - CAS 124182-57-6 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Adenosine A2A Receptor Agonist I, CGS 21680, Hydrochloride - CAS 124182-57-6 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      119137

      Références bibliographiques

      Aperçu de la référence bibliographique
      Willians, A. J., et al. 2012. Inflammation. 35, 614.
      Mazzon, E. et al. 2011. J Rheumatol. 38, 2119,
      Martire, A., et al. 2007. Neurosci Lett. 417, 78.
      Chou, S. Y., et al, 2005. Journ Neurochem. 93, 310.
      Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol.362 382.
      Phillis, J. W., et al. 1990.Brain Res. 509, 328.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision14-November-2019 JSW
      SynonymsCGS-21680, CGS21680, 3-(4-(2-((6-amino-9-((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl)amino)ethyl)phenyl)propanoic acid
      DescriptionA xanthin derivative that acts as a potent agonist of adenosine A2A receptors (Ki = 27 nM). Exhibits reduced affinity for A2B receptors (Ki = 67 nM), but offers greater selectivity over A1R (Ki = 290 nM) and A3R (88.8 µM). Exerts an anti-inflammatory effect during chronic inflammation and ameliorates the tissue damage associated with collagen-induced arthritis. Also shown to reduce CCR7 Protein Expression in THP1 macrophages. Shown to delay the progressive deterioration of motor performance and prevent a reduction in brain weight in murine model of Huntington's disease.
      FormWhite solid
      FormulationSupplied as a hydrochloride salt.
      Intert gas (Yes/No) Packaged under inert gas
      CAS number124182-57-6
      Chemical formulaC₂₃H₂₉N₇O₆ • HCl
      Structure formulaStructure formula
      Purity≥96% by HPLC
      SolubilityDMSO (100 mM)
      Storage -20°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesWillians, A. J., et al. 2012. Inflammation. 35, 614.
      Mazzon, E. et al. 2011. J Rheumatol. 38, 2119,
      Martire, A., et al. 2007. Neurosci Lett. 417, 78.
      Chou, S. Y., et al, 2005. Journ Neurochem. 93, 310.
      Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol.362 382.
      Phillis, J. W., et al. 1990.Brain Res. 509, 328.